Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;10(1):271-281.
doi: 10.1007/s13346-019-00685-4.

The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration

Ying Jiang  1 , Azizi Ray  1 , Mohammad Shajid Ashraf Junaid  1 , Sonalika Arup Bhattaccharjee  1 , Kayla Kelley  1 , Ajay K Banga  1 , Bruce E Blough  2 , Kevin S Murnane  3
Affiliations

The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration

Ying Jiang et al. Drug Deliv Transl Res. 2020 Feb.

Abstract

3-Fluoroamphetamine (also called PAL-353) is a synthetic amphetamine analog that has been investigated for cocaine use disorder (CUD), yet no studies have characterized its pharmacokinetics (PK). In the present study, we determined the PK of PAL-353 in male Sprague Dawley rats following intravenous bolus injection (5 mg/kg). Plasma samples were analyzed using a novel bioanalytical method that coupled liquid-liquid extraction and LC-MS/MS. The primary PK parameters determined by WinNonlin were a C0 (ng/mL) of 1412.09 ± 196.12 and a plasma half-life of 2.27 ± 0.67 h. As transdermal delivery may be an optimal approach to delivering PAL-353 for CUD, we assessed its PK profile following application of 50 mg of transdermal gel (10% w/w drug over 5 cm2). The 10% w/w gel resulted in a short lag time, sustained delivery, and a rapid clearance in plasma immediately after removal. The rodent PK data were verified by examining in vitro permeation through human epidermis mounted on Franz diffusion cells. An in vitro-in vivo correlation (IVIVC) analysis was performed using the Phoenix IVIVC toolkit to assess the predictive relationship between rodent and human skin absorption/permeation. The in vitro permeation study revealed a dose-proportional cumulative and steady-state flux with ~ 70% of drug permeated. The fraction absorbed in vivo and fraction permeated in vitro showed a linear relationship. In conclusion, we have characterized the PK profile of PAL-353, demonstrated that it has favorable PK properties for transdermal administration for CUD, and provided preliminary evidence of the capacity of rodent data to predict human skin flux.

Keywords: 3-Fluoroamphetamine; Cocaine use disorder; In vitro-in vivo correlation; Intravenous; Pharmacokinetics; Transdermal.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

None of the authors has a financial relationship with the sponsor of the research, which was the Georgia Research Alliance. The Georgia Research Alliance is a state government funded agency.

Ajay Banga and Kevin Murnane are cofounders of DD Therapeutics, a for-profit startup company that aims to commercialize drug-delivery technology.

Ajay Banga, Kevin Murnane, and Ying Jiang are co-inventors on a patent pending for transdermal use of phenethylamine monoamine releasers that is owned by Mercer University.

Azizi Ray, Mohammad Shajid Ashraf Junaid, Sonalika Arup Bhattaccharjee, Kayla Kelley, and Bruce Blough have no conflicts of interest to declare.

All institutional and national guidelines for the care and use of laboratory animals were followed.

Figures

Fig. 1
Fig. 1
A representative chromatogram of PAL-353 at the transition of 154.3–109.2 m/z for spiked plasma extraction sample at 0.5 ng/mL (signal-to-noise ratio=10.5).
Fig. 2
Fig. 2
Plasma profile of PAL-353 following intravenous bolus injection and transdermal administration of 10% w/w gel (n=3, mean ± SD).
Fig. 3
Fig. 3
The in vitro permeation profile of PAL-353 from 5 and 10% w/w gels. The percentage of delivery at 9 h and 24 h were labeled under the symbol corresponding to those sample points. (n=4, mean ± SD).
Fig. 4
Fig. 4
The analysis of the predictive relationship between in vitro permeation and in vivo absorption of PAL-353.
See this image and copyright information in PMC

References

    1. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: The state of the science. Vol. 162, American Journal of Psychiatry; 2005. p. 1432–40. - PubMed
    1. Vocci FJ, Appel NM. Approaches to the development of medications for the treatment of methamphetamine dependence. Vol. 102, Addiction; 2007. p. 96–106. - PubMed
    1. Volkow ND, Li T-K. Science and Society: Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci. 2004. December;5(12):963–70. - PubMed
    1. Howell LL, Murnane KS. Nonhuman Primate Neuroimaging and the Neurobiology of Psychostimulant Addiction. Ann N Y Acad Sci. 2008. October;1141(1):176–94. - PMC - PubMed
    1. Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL. Dopamine transporter-related effects of modafinil in rhesus monkesy. Psychopharmacology (Berl). 2010. June 13;210(3):439–48. - PMC - PubMed

Publication types